Expertise
Areas of Specialization
Research Clusters
-
Associate Professor
McMaster School of Biomedical Engineering
Overview
Katherine Zukotynski is an Associate Professor in the Departments of Medicine and Radiology at McMaster University. After completing an undergraduate degree in Engineering Science at the University of Toronto, Dr. Zukotynski completed medical training followed by residency in radiology, also at the University of Toronto. She completed nuclear medicine training through the Joint Program in Nuclear Medicine at Harvard in 2009. She was a staff radiologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital from 2009 through 2012 and Instructor at Harvard Medical School. Subsequently she was a staff radiologist at Sunnybrook Health Sciences Centre from 2012 through 2015 and Assistant Professor at the University of Toronto. She is board certified in nuclear cardiology as well as in nuclear medicine and radiology in both the United States and Canada.
Dr. Zukotynski is involved in medical imaging research. Her main areas of research are in PET/CT, particularly as it relates to oncology, neurodegenerative disease and machine learning. She received the RSNA Research and Education Foundation Roentgen Resident/ Fellow Research Award first as a radiology resident and then as a nuclear medicine resident. She held an RSNA Research Scholar Grant from 2012-2014 and currently holds approximately $5M in grant funding for molecular imaging, predominantly in prostate cancer research.
MD, 2002, University of Toronto
Dr. Zukotynski is Secretary/Treasurer of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), President of the SNMMI PET Center of Excellence, and past President of the SNMMI Eastern Great Lakes Chapter. She is Chair of the American Roentgen Ray Society (ARRS) Nuclear Medicine Section, Chair of the Research and Education Public Relations Committee for the Radiologic Society of North America (RSNA) and a board member of the American College of Nuclear Medicine (ACNM).
A sample of her most recent publications include:
[1] Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, Benard F, Black S, Zukotynski K. “Part 1: Introduction to Machine Learning in the Nuclear Medicine Context” J Nucl Med; in press.
[2] Fahey F, Christian P, Zukotynski K, Sexton-Stallone B, Kiss C, Clarke B, Onar-Thomas A, Young Poussaint T. “Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network” J Nucl Med; in press.
[3] Schwarz SW, Decristoforo C, Goodbody AE, Singhal N, Saliba S, Ruddock P, Zukotynski K, Ross AC. “Harmonization of United States, European Union and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals – Is This Possible?” J Nucl Med; [Epub ahead of print].
[4] Choudhury A, Gray K, Supko J, Harshman L, Taplin ME, Pace A, Farina M, Zukotynski K, Bernard B, Kantoff P, Pomerantz M, Sweeney C. “A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer”. The Prostate; [Epub ahead of print].
[5] Li J, Xu R, Kim CK, Bénard F, Kapoor A, Bauman G, Zukotynski K. “18F-DCFPyL PET/CT in Oncocytoma”. Clin Nucl Med; 43(12): 921-924 (2018). PMID: 30300203.
[6] Sanli Y, Zukotynski K, Mittra E, Chen D, Nadel H, Niederkohr R, Subramaniam RM. “Update 2018: 18F-FDG PET/CT & PET/MRI in Head and Neck Cancer”. Clin Nucl Med; 43(12): e439-e452 (2018). PMID: 30394934
[7] Zukotynski K, Kuo PH, Mikulis D, Rosa-Neto P, Strafella A, Subramaniam RM, Black SE. “PET/CT of Dementia”. AJR; 211(2): 246-259 (2018). PMID: 29949415
[8] Alibhai SMH, Zukotynski K, Walker-Dilks C. “Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer”. Ann Intern Med; 168(6):459-460 (2018). PMID: 29554680
[9] Simon M, Zukotynski K, Naeger D. “Five things to know about: Pulmonary nodules as incidental findings”. CMAJ; 190(6):E167 (2018). PMID: 29440337
[10] Zukotynski K, Valliant J, Bénard F, Rowe SP, Kim CK, Pomper MG, Cho SY. “Flare on serial prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: First observations”. Clin Nucl Med; 43(3):213-216 (2018). PMID: 29356735
[11] Jadvar H, Colletti P, Delgado-Bolton R, Esposito G, Krause B, Iagaru A, Nadel H, Quinn D, Rohren E, Subramaniam R, Zukotynski K, Kauffman J, Ahuja S, Griffeth LK. “Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease”. J Nucl Med; 58(12):2026-2037 (2017). PMID: 29025980
[12] Zukotynski KA, Kim CK. “Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers”. PET Clin; 12(4):393-405 (2017). PMID: 28867111
[13] Alibhai SMH, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Tomlinson GA, Winquist E. “Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis”. Ann Intern Med; 167(5):341-350 (2017). PMID: 28785760
[14] Zukotynski KA, Vajapeyam S, Fahey FH, Kocak M, Brown D, Ricci KI, Onar-Thomas A, Fouladi M, Poussaint TY. “Correlation of 18F-FDG PET and MR Apparent Diffusion Coefficient (ADC) Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium”. J Nucl Med; 58(8):1264-1269 (2017). PMID: 28360212
[15] Rakvongthai Y, Fahey F, Tepmongkol S, Vutrapongwatana U, Zukotynski K, El Fakhri G, Ouyang J. “Joint Reconstruction of Ictal/inter-ictal SPECT Data for Improved Epileptic Foci Localization”. Medical Physics; 44(4):1437-1444 (2017). PMID: 28211105
[16] Alibhai SMH*, Zukotynski K*, Walker-Dilks C, Emmenegger U, Finelli A, Morgan SC, Hotte SJ, Winquist E, Cancer Care Ontario Genitourinary Cancer Disease Site Group. “Bone Health and Bone-targeted Therapies for Prostate Cancer: a Program in Evidence-based Care–Cancer Care Ontario Clinical Practice Guideline”. Clin Oncol; 29(6):348-55 (2017). *co-first authors. PMID: 28169118
[17] Kim CK, Zukotynski KA. “Desirable Properties of Radiopharmaceuticals for Sentinel Node Mapping in Patients with Breast Cancer Given the Paradigm Shift in Patient Management”. Clin Nucl Med; 42(4):275-279 (2017). PMID: 28166148
[18] Zukotynski KA, Gerbaudo VH. “Molecular Imaging and Precision Medicine in Lung Cancer”, PET Clin; 12(1):53-62 (2017). PMID: 27863566
[19] Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen D, Zukotynski K, Kostakoglu L. “Standardized Response Assessment Criteria and their Applications in Lymphoma: Part 2”, J Nucl Med; 58(1):13-22 (2017). PMID: 27879369
[20] Zukotynski K, Jadvar H, Hope T, Subramaniam RM, Van Loon K, Madhulika V, Niederkohr RD. “SNMMI Comment on the 2016 Society of Surgical Oncology “Choosing Wisely” Recommendation on the Use of PET/CT in Colorectal Cancer.” J Nucl Med; 58(1):11-12 (2017). PMID: 27688471
[21] McKay RR, Erner L, Mostaghel EA, Lis RT, Voznesensky O, Zhang Z, Marck B, Matsumoto Am, Domachevsky L, Zukotynski KA, Bhasin MK, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME. “A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer”. Clin Cancer Res; 23(4):935-945 (2017). PMID: 27683182